SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
BMY (bristol myers squibb)
An SI Board Since January 1997
Posts SubjectMarks Bans Symbol
194 21 0 BMY
Emcee:  trevor john wilkinson Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
169In a maintenance setting, it's pretty hard to beat a placebo, crazy as that DewDiligence_on_SI-11/26/2018
168Yes, but it was *placebo* they have to bit! Pathetic! :-( So, maintenance = IGNMiljenko Zuanic-11/26/2018
167In many kinds of cancer, the first-line maintenance setting is a difficult placeDewDiligence_on_SI-11/26/2018
166It is rely going on my nerve, right now! CM-451 failed OS! finance.yahoo.comMiljenko Zuanic-11/26/2018
165To me, looks like it is going nowhere, until CM227 is out! By that time, God HEMiljenko Zuanic-11/21/2018
164The analyst (Andrew Baum [Citi] ) should've demanded a clarification by PerlDewDiligence_on_SI-10/29/2018
163So, why he did not spell out what are that *REASONS*? What IO candidate he develMiljenko Zuanic-10/29/2018
162Enigmatic TMB comment by Roger Perlmutter on MRK’s 3Q18 CC: I think that the queDewDiligence_on_SI-10/29/2018
161No comments on MRK's 3Q18 CC about KEYNOTE-548; CC comments on in-house CTLADewDiligence_on_SI-10/29/2018
160CM-459, 1L HCC, Opdivo v Sorafenib: clinicaltrials.gov <The Primary CompletioMiljenko Zuanic-10/25/2018
159BMY respond on Q about MRK anti-CTLA4 Abs (MK-1308) presented at ESMO: <Alex,Miljenko Zuanic-10/25/2018
158For KEYNOTE-598, MRK hasn’t disclosed anything beyond what’s listed at ct.gov, aDewDiligence_on_SI-10/25/2018
157I do not follow MRK! Have any info on Keytruda + Y (KEYNOTE-598, clinicaltrialsMiljenko Zuanic-10/25/2018
156Yes, it was not. And, we do not know is Opdivo troubling component, or NKTR-214?Miljenko Zuanic-10/25/2018
155CC answer re Opdivo/NKTR-214 in NSCLC was not reassuring,DewDiligence_on_SI-10/25/2018
154RE: 3Qcc On TMB they continue to fuck around without any outcome (definitely theMiljenko Zuanic-10/25/2018
1535% drop today is not bad under the circumstances. Most newswires are reporting FDewDiligence_on_SI-10/22/2018
152finance.yahoo.com That Y play significant rule in O + Y is well known (EU agencMiljenko Zuanic-10/21/2018
151May 20, 2019 :-)DewDiligence_on_SI-10/19/2018
150Further "oil on fire", uncertainty level steady incense....where is ENMiljenko Zuanic-10/19/2018
149 P109 Clinical efficacy of immune checkpoint inhibitors in patients with small cMiljenko Zuanic-10/1/2018
148promising results: seekingalpha.comMiljenko Zuanic-9/13/2018
147Not a bad argue, but it does lack details: seekingalpha.comMiljenko Zuanic-8/27/2018
146 Eliquis is a monster drug. (Too bad BMY didn't retain higher % of profits.)Miljenko Zuanic-7/26/2018
145Eliquis is a monster drug. (Too bad BMY didn't retain higher % of profits.)DewDiligence_on_SI-7/26/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News